Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
July 22 2021 - 8:13PM
Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device
company focused on addressing the underlying causes of the world's
most prevalent eye diseases, today announced that data from
multiple retrospective and prospective clinical studies of the
OMNI® Surgical System and TearCare® System will be presented at the
2021 American Society of Cataract and Refractive Surgery (ASCRS)
Annual Meeting. The in-person conference will take place July 23-27
in Las Vegas.
A total of five papers have been accepted for presentation.
Details of the presentations are as follows (all times are Pacific
Daylight Time (PDT)):
Saturday, July 24
Session Title: “Efficacy of Ab Interno
Canaloplasty Followed by Trabeculotomy in Pseudophakic Eyes with
Open-Angle Glaucoma”Session: Minimally Invasive
Glaucoma Surgery (MIGS)Presenter: Adam Bleeker,
O.D. Location: MBCR - Level 2, Surf
CDTime: 1:30 PM
Session Title: “Ab Interno Canaloplasty and
Trabeculotomy in Pseudophakic Eyes with Mild-Moderate Open Angle
Glaucoma: Prospective Multicenter Trial
(ORION)”Session: Minimally Invasive Glaucoma
Surgery (MIGS)Presenter: Mark J. Gallardo, M.D.
Location: MBCR - Level 2, Surf
CDTime: 2:00 PM
Session Title: “Novel Blink-Assisted Meibomian
Gland Procedure for Safe and Effective Treatment of Dry Eye: A
Prospective, Masked, Multicenter Trial
(CHEETAH)”Session: Ocular
SurfacePresenter: David Wirta, M.D.
Location: MBCR - Level 2, Surf
EFTime: 2:11 PM
Session Title: “Effect of Canaloplasty and
Trabeculotomy on Intraocular Pressure in Eyes with Open Angle
Glaucoma Undergoing Phacoemulsification”Session:
Minimally Invasive Glaucoma Surgery
(MIGS)Presenter: Arkadiy Yadgarov,
M.D.Location: MBCR - Level 2, Surf
CDTime: 2:30 PM
Sunday, July 25
Session Title: “Canaloplasty Plus Trabeculotomy
with Cataract Surgery for Mild-Moderate Open Angle Glaucoma:
Prospective Clinical Trial Results (GEMINI)”
Session: Minimally Invasive Glaucoma Surgery
(MIGS) IIPresenter: Mark F. Pyfer, M.D.,
F.A.C.S.Location: MBCR - Level 2, Surf
EFTime: 10:10 AM
About Sight SciencesFounded in 2011, Sight
Sciences develops and commercializes intelligently designed and
engineered products that target the underlying causes of the
world’s most prevalent eye diseases. The company currently markets
two products, the OMNI® Surgical System and the TearCare® System.
For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight
Sciences.© 2021 Sight Sciences. All rights reserved.
Forward-Looking StatementsThis press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. When used herein,
words including “anticipate,” “will,” and similar expressions are
intended to identify forward-looking statements. In addition, any
statements or information that refer to expectations, beliefs,
plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon Sight Sciences’ current expectations and
various assumptions. Actual results, levels of activity,
performance, achievements and events could differ materially from
those stated, anticipated or implied by such forward-looking
statements. While the Company believes that its assumptions are
reasonable, Sight Sciences may not realize its expectations, and
its beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including the
factors discussed under the caption “Risk Factors” in its
registration statements on Form S-1, as such factors may be updated
from time to time in its other filings with the SEC, which are
accessible on the SEC’s website at www.sec.gov. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
Sight Sciences may elect to update such forward-looking statements
at some point in the future, except as required by law, it
disclaims any obligation to do so, even if subsequent events cause
our views to change. These forward-looking statements should not be
relied upon as representing Sight Sciences’ views as of any date
subsequent to the date of this press release
Media contact:Shay
SmithHealth+Commerce707.971.9779shay@healthandcommerce.com
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sight Sciences (NASDAQ:SGHT)
Historical Stock Chart
From Apr 2023 to Apr 2024